Research trends and hotspots in the immune microenvironment related to hepatocellular carcinoma: A bibliometric and visualization study

Table 4 List of co cited literature

Rank	Title	Journal IF (2021)	Author(s)	Total citations
1	Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	CA-A Cancer Journal for Clinicians (IF = 354.7)	Sung H	393
2	Nivolumab in patients with advanced HCC (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial	Lancet (IF = 168.9)	El-Khoueiry AB	348
3	Atezolizumab plus Bevacizumab in Unresectable HCC	New England Journal of Medicine (IF = 158.5)	Finn RS	333
4	Pembrolizumab in patients with advanced HCC previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial	Lancet Oncology (IF = 51.1)	Zhu AX	259
5	HCC	Nature Reviews Disease Primers (IF = 81.5)	Llovet JM	246
6	HCC	New England Journal of Medicine (IF = 158.5)	Villanueva A	228
7	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable HCC: A randomised phase 3 non-inferiority trial	Lancet (IF = 168.9)	Kudo M	196
8	A global view of HCC: trends, risk, prevention and management	Nature Reviews Gastroenterology and Hepatology (IF = 65.1)	Yang JD	194
9	Pembrolizumab As Second-Line Therapy in Patients With Advanced HCC in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial	Journal of Clinical Oncology (IF = 45.4)	Finn RS	186
10	Molecular therapies and precision medicine for HCC	Nature Reviews Clinical Oncology (IF = 78.8)	Llovet JM	162

HCC: Hepatocellular carcinoma; IF: Impact factor.